Bernard Zinman

Bernard Zinman

Departments of Endocrinology and Metabolism, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. | Division of Endocrinology, University of ...

KOL Resume for Bernard Zinman  (diabetes, type 2, diabetes type 2, type, mellitus)


Departments of Endocrinology and Metabolism, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada


Sinai Health and the Department of Medicine, University of Toronto, Toronto, ON, Canada


Sinai Health System, Mount Sinai Hospital, Toronto, ON, Canada

Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA

The George Institute for Global Health, UNSW Sydney, Sydney, Australia


Department of Medicine, University of Toronto, 1 King's College Circle, M5S 1A8, Toronto, ON, Canada

Novo Nordisk A/S, Søborg, Denmark

Boehringer Ingelheim, Ingelheim, Germany

University of Mississippi, Jackson, MS, USA


Prominent publications by Bernard Zinman

KOL Index score: 22826

BACKGROUND: In a pooled analysis of short-term trials, short-term treatment with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria. In this exploratory analysis of the EMPA-REG OUTCOME trial, we report the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 diabetes and established cardiovascular disease, according to patients' baseline albuminuria ...

Known for Type 2 Diabetes |  Empagliflozin Placebo |  Uacr Baseline |  Creatinine Ratio |  Cardiovascular Disease
KOL Index score: 21400

BACKGROUND: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We ...

Known for Cardiovascular Disease |  Diabetes Mellitus |  Type 2 |  Chronic Kidney |  Patients Egfr
KOL Index score: 18999

Importance: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease.

Objective: To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV outcomes and kidney outcomes in patients with type 2 diabetes at high risk of CV and kidney events.

Design, Setting, and Participants: ...

Known for Renal Risk |  Type 2 Diabetes |  Linagliptin Placebo |  Cardiovascular Events |  Clinical Trial
KOL Index score: 18580

Aims/hypothesisAfter coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the risk of cardiovascular death by 38%, all-cause mortality by 32%, hospitalisation for heart failure by 35% and incident or worsening nephropathy by 39% vs placebo when given in addition to standard ...

Known for Type 2 Diabetes |  Cardiovascular Events |  Heart Failure |  Empagliflozin Placebo |  Coronary Artery
KOL Index score: 18576

OBJECTIVE: Gestational impaired glucose tolerance (GIGT), defined by a single abnormal value on antepartum 3-h oral glucose tolerance test (OGTT), is a metabolically heterogeneous disorder. Indeed, the antepartum metabolic phenotype of women with a single abnormal value at 1 h during the OGTT (1-h GIGT) resembles that of women with gestational diabetes mellitus (GDM), whereas GIGT at 2 or 3 h (2/3-h GIGT) is similar to normal glucose tolerance (NGT). Thus, we hypothesized that 1-h GIGT ...

Known for Isolated Hyperglycemia |  Glucose Tolerance |  Diabetes Mellitus |  1h Gigt |  Gct Ngt
KOL Index score: 18327

AIM: To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week interim analysis of a large, randomized, double-blind, multicentre study. The primary objective was to demonstrate non-inferiority of vildagliptin vs. glimepiride in glycosylated haemoglobin (HbA(1c)) reduction at week 52.

METHODS: Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5%) and receiving a stable ...

Known for Metformin Monotherapy |  Patients Glimepiride |  Hypoglycaemia Vildagliptin |  Diabetes Mellitus |  Type 2
KOL Index score: 18262

BACKGROUND: Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study ...

Known for Diabetes Mellitus |  Type 2 |  Heart Failure |  Kidney Disease |  Renal Risk
KOL Index score: 17730

OBJECTIVE: The purpose of this study was to test the hypothesis that any degree of abnormal glucose homeostasis detected on antepartum screening for gestational diabetes mellitus (GDM) should be associated with an increased risk of postpartum pre-diabetes or diabetes.

RESEARCH DESIGN AND METHODS: In this prospective cohort study, 487 women underwent 1) antepartum GDM screening by a glucose challenge test (GCT) and a diagnostic oral glucose tolerance test (OGTT) and 2) postpartum ...

Known for Gct Ngt |  Glucose Intolerance |  Future Risk |  Gigt Gdm |  Postpartum Diabetes
KOL Index score: 17446

BACKGROUND: Semaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) analogue for type 2 diabetes. Few clinical trials have reported on the concomitant use of GLP-1 receptor agonists with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. We aimed to investigate the efficacy and safety of semaglutide when added to SGLT-2 inhibitor therapy in patients with inadequately controlled type 2 diabetes.

METHODS: The SUSTAIN 9 double-blind, parallel-group trial was done at 61 centres in six ...

Known for Patients Semaglutide |  Type 2 |  Controlled Trial |  Hba1c Baseline |  Inhibitor Treatment
KOL Index score: 17323

OBJECTIVE: To revise and expand the 1992 edition of the clinical practice guidelines for the management of diabetes in Canada incorporating recent advances in diagnosis and outpatient management of diabetes mellitus and to identify and assess the evidence supporting these recommendations.

OPTIONS: All aspects of ambulatory diabetes care, including organization, responsibilities, classification, diagnosis, management of metabolic disorders, and methods for screening, prevention and ...

Known for Complications Diabetes |  Clinical Practice Guidelines |  Evidence Recommendations |  Metabolic Control |  Diagnosis Management
KOL Index score: 17281

Aims/hypothesisThe double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) assessed the cardiovascular safety of insulin degludec. The incidence and rates of adjudicated severe hypoglycaemia, and all-cause mortality were also determined. This paper reports a secondary analysis investigating associations of severe hypoglycaemia with cardiovascular outcomes and ...

Known for Severe Hypoglycaemia |  Allcause Mortality |  Risk Mace |  Insulin Degludec |  Cardiovascular Outcomes
KOL Index score: 17154

BACKGROUND: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and all-cause death, and hospitalization for heart failure. We investigated whether these effects varied across the spectrum of ...

Known for Cardiovascular Risk |  Heart Failure |  Outcome Trial |  Empagliflozin Placebo |  Prior Myocardial Infarction
KOL Index score: 17055

BACKGROUND: An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population.

METHODS: In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy ...

Known for Diabetes Therapy |  Filtration Rate |  Type 1 |  Estimated Gfr |  Edic Study
KOL Index score: 17031

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy ...

Known for Rosiglitazone Metformin |  Glycemic Durability |  Monotherapy Failure |  Plasma Glucose |  Ldl Diabetes Mellitus
KOL Index score: 16996

OBJECTIVE: Glucose intolerance in pregnancy predicts an increased risk of future type 2 diabetes mellitus (T2DM) that is proportional to the severity of antepartum dysglycemia (i.e., highest in women with gestational diabetes mellitus [GDM], followed by those with milder dysglycemia). However, the pathophysiologic changes driving this risk are not known. Thus, we evaluated the longitudinal changes in β-cell function, insulin sensitivity, and glycemia in the first 3 years postpartum after ...

Known for Insulin Sensitivity |  Glucose Intolerance |  Cell Function |  3 Years |  Type 2 Diabetes


Bernard Zinman: Influence Statistics

Sample of concepts for which Bernard Zinman is among the top experts in the world.
Concept World rank
empagliflozin cardiorenal outcomes #1
day nph #1
t45s #1
lp csii #1
participants iit #1
iit impact #1
gain gain women #1
gdm nongdmlga #1
756±286mg #1
skinfold thickness sft #1
48 weeks remitters #1
gigt 1 #1
peak glucose #1
int q4 int #1
gdm lga delivery #1
gigt groups gdm #1
gct ngt gct #1
timing glucose peak #1
subjects g319s mutation #1
reductions empagliflozin #1
dairy intake markers #1
remitters remission #1
renal outcomes 95 #1
weight empagliflozin #1
hhf death hhf #1
metabolic hormonal response #1
insulin aep control #1
aucgluc #1
βcell function glycemia #1
linagliptin acd #1
sustained microalbuminuria #1
reduced cognition type #1
g148 variant #1
164224 #1
a1c degludec #1
g319s hnf1a #1
gdm 1h gigt #1
prevalence pediatric overweight #1
paraoxonase2 gene #1
kidney risk nrp #1
postpartum insulin #1
oads daily degludec #1
insulin lispro lp #1
asians bmi categories #1
t1d day #1
metformin comorbidity #1
plasma crp hnf1a #1
prior lactation #1
pinteraction insulin #1
current glucose intolerance #1

Key People For Type 2 Diabetes

Top KOLs in the world
David Richard Matthews
type 2 diabetes sri lanka growth hormone
Frank B Hu
type 2 diabetes cardiovascular disease physical activity
Rury R Holman
type 2 diabetes cardiovascular disease impaired glucose tolerance
David Matthew Nathan
type 2 diabetes insulin resistance cardiovascular disease
John B Buse
type 2 diabetes insulin degludec cardiovascular outcomes
Tuomilehto Tuomilehto
type 2 diabetes blood pressure north karelia

Bernard Zinman:Expert Impact

Concepts for whichBernard Zinmanhas direct influence:Type 2 diabetes,  2 diabetes,  Type 2,  Type 1 diabetes,  Diabetes mellitus,  Insulin resistance,  Insulin sensitivity,  Heart failure.

Bernard Zinman:KOL impact

Concepts related to the work of other authors for whichfor which Bernard Zinman has influence:Type 2 diabetes,  Heart failure,  Insulin resistance,  Metabolic syndrome,  Cardiovascular disease,  Glycemic control,  Sglt2 inhibitors.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Departments of Endocrinology and Metabolism, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. | Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada. | Lunenfeld-Tanenbaum Research Institut

FREE Custom List